CoChat
Sign Up
Cited by 809Cervical Cancer and HPV ResearchWomen's cancer prevention and managementReproductive tract infections research

Human papillomavirus and cervical cancer

Open access
Okunade, Kehinde Sharafadeen·2020·Journal of Obstetrics and Gynaecology
DOI 10.1080/01443615.2019.1634030PMC PMC7062568
Open this paper in CoChat — free account

Abstract

Cervical cancer is by far the most common HPV-related disease. About 99.7% of cervical cancer cases are caused by persistent genital high-risk human papillomavirus (HPV) infection. Worldwide, cervical cancer is one of the most common cancer in women with an estimated 528,000 new cases reported in 2012. Most HPV infections clear spontaneously but persistent infection with the oncogenic or high-risk types may cause cancer of the oropharynx and anogenital regions. The virus usually infects the mucocutaneous epithelium and produces viral particles in matured epithelial cells and then causes a disruption in normal cell-cycle control and the promotion of uncontrolled cell division leading to the accumulation of genetic damage. There are currently two effective prophylactic vaccines against HPV infection, and these comprise of HPV types 16 and 18, and HPV types 6, 11, 16 and 18 virus-like particles. HPV testing in the secondary prevention of cervical cancer is clinically valuable in triaging low-grade cytological abnormalities and is also more sensitive than cytology as a primary screening. If these prevention strategies can be implemented in both developed and developing countries, many thousands of lives could be saved.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/01443615.2019.1634030

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 71

  1. [1]ACOG – American College of Gynecologists and Obstetricians. Practice Bulletin No. 140: Management of abnormal cervical cancer screening test results and cervical cancer precursors. Obstet Gynecol 2013; 122: 1338– 67. 24264713
  2. [2]ACOG – American College of Obstetricians and Gynecologists. Committee Opinion No. 704: Human papillomavirus vaccination. Obstet Gynecol 2017; 129: e173– 8 28346275
  3. [3]Adam E, Berkova Z, Daxnerova Z, Icenogle J, Reeves WC, Kaufman RH. Papillomavirus detection: demographic and behavioral characteristics influencing the identification of cervical disease. Am. J. Obstet. Gynecol 2000; 182: 257– 264. 10694321
  4. [4]Agida T, Akaba G, Isah A, Ekele B. Knowledge and perception of human papilloma virus vaccine among the antenatal women in a Nigerian tertiary hospital. Niger Med J. 2015; 56(1): 23– 27. 25657489 PMC4314855
  5. [5]Andersson S, Rylander E, Larsson B, Strand A, Silfversvard C, Wilander E. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur. J. Cancer 2001; 37: 246– 250. 11166153
  6. [6]Appleby P, Beral V, Berrington de Gonzáles A, Colin D, Franceschi S, Green J, Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006; 119: 1108– 1124. 16570271
  7. [7]Apt D, Watts RM, Suske G, Bernard U. High Sp1/Sp3 ratios in epithelial cells during epithelial differentiation and cellular transcription correlate with the activation of the HPV-16 promoter. Virology 1996; 224: 281– 291. 8862423
  8. [8]Autier P, Coibion M, Huet F, Grivegnee AR. Transformation zone location and intraepithelial neoplasia of the cervix uteri. Br J Cancer 1996; 74: 488– 490. 8695371 PMC2074626
  9. [9]Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys. J 1991; 60: 1445– 1456. 1663794 PMC1260204
  10. [10]Bao YP, Li N, Smith JS, Qiao YL; ACCPAB members: human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer. 2008; 18(1): 71– 9. 17466054
  11. [12]Brisson J, Morin K, Fortier M, Roy M, Bouchard C, Leclerc J, Risk factors for cervical intraepithelial neoplasia: differences between low and high-grade lesions. Am. J. Epidemiol. 1994; 40: 700– 710. 7942772
  12. [13]Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003; 16(1): 1– 17. 12525422 PMC145302
  13. [14]Burk RD, Kelly P, Feldman J, Bromberg J, Vermund SH, Deltovitz JA, Declining presence of cervicovaginal human papilllomavirus infection with age is independent of other risk factors. Sex. Transm. Dis. 1996; 23: 333– 341. 8836027
  14. [15]Calore EE, Pereira SMM, Cavaliere MJ. Progression of cervical lesions in HIV-seropositive women: a cytological study. Diagn. Cytopathol 2001; 24: 117– 119. 11169890
  15. [16]Capra G, Giovannelli L, Matranga D, Bellavia C, Guarneri MF, Fasciana T, Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily. Hum Vaccin Immunother. 2017; 13(8): 1839– 1843. 28594305 PMC5557238
  16. [17]Cárdenas-Turanzas M, Nogueras-Gonzalez GM, Scheurer ME, Adler-Storthz K, Benedet JL, Beck JR, The Performance of Human Papillomavirus High-Risk DNA Testing in the Screening and Diagnostic Settings Cancer Epidemiol Biomarkers Prev. 2008; 17(10): 2865– 2871. 18843032 PMC2705895
  17. [18]Castle PE. Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J Low Genit Tract Dis. 2004; 8: 224– 230. 15874868
  18. [19]Catarino R, Petignat P, Dongui G, Vassilakos P. Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices. World J Clin Oncol. 2015; 6(6): 281– 290. 26677441 PMC4675913
  19. [20]Chua KL, Hjerpe A. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 1996; 77: 121– 127. 8630917
  20. [21]Conely LK, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminate and intraepithelial neoplasia; a prospective cohort study. Lancet 2002; 359(9301): 108– 113. 11809252
  21. [22]Cubie HA, Seagar AL, Beattie GJ, Monaghan S, Williams ARW. A longitudinal study if HPV detection and cervical pathology in HIV infected women. Sex. Transm. Infect. 2000; 76: 257– 261. 11026879 PMC1744169
  22. [23]de Araujo Souza PS, Villa LL. Genetic susceptibility to infection with human papillomavirus and development of cervical cancer in women in Brazil. Mutat Res. 2003; 544(2-3): 375– 83. 14644340
  23. [24]Denny L Cervical Cancer: Prevention and Treatment. Discov Med. 2012; 14(75): 125– 131 22935209
  24. [25]de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. Worldwide Prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2003; 7(7): 453– 9. 17597569
  25. [26]Erickson BK, Alvarez RD, Huh WK. Human papillomavirus: What every provider should know. Am. J. Obstet. Gynecol. 2013; 208(3): 169– 175. 23021131 PMC3549042
  26. [27]Ezenwa BN, Balogun MR, Okafor IP. Mothers’ human papilloma virus knowledge and willingness to vaccinate their adolescent daughters in Lagos, Nigeria. Int J Womens Health. 2013; 5: 371– 377. 23874123 PMC3711756
  27. [28]Favre M Structural polypeptides of rabbit, bovine, and human papillomaviruses. J. Virol. 1975; 15: 1239– 1247. 167184 PMC354579
  28. [29]Franco EL. Cancer causes revisited: human papillomavirus and cervical neoplasia. J. Natl. Cancer Inst. 1995; 87: 779– 780. 7791221
  29. [30]Gichangi P, Estambale B, Bwayo J, Rogo K, Ojwang S, Opiyo A Knowledge and practice about cervical cancer and Pap smear testing among patients at Kenyatta National Hospital, Nairobi, Kenya. Int J Gynecol Cancer. 2003; 13(6): 827– 833. 14675320
  30. [31]Giorgi C, Franconi R, Rybicki EP. Human papillomavirus vaccines in plants. Expert. Rev. Vaccin. 2010; 9(8): 913– 924. 20673013
  31. [33]Harris TG, Burk RD, Palesky JM, Massad S, Bang JY, Anastos K, Incidence of Cervical Squamous Intraepithelial Lesions Associated with HIV serostatus, CD4 Cell Counts, and human papillomavirus test results. JAMA 2005; 293(12): 1471– 1476. 15784870
  32. [34]Harro CD, Pang Y-YS, Roden RBS, Hildesheim A, Wang Z, Reynolds MJ, Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 2001; 93: 284– 292. 11181775
  33. [35]Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 1998; 338: 413– 428. 9459645
  34. [36]Holcomb K, Abulafia O, Matthews RP, Chapman JE, Borges A, Lee YC, The significance of ASCUS cytology in HIV-positive women. Gynecol Oncol. 1999; 75(1): 118– 21. 10502437
  35. [37]Huh WK, Ault KA, Chelmow D. Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidance. J Lower Gen Tract Dis 2015; 19: 91– 96 25574659
  36. [38]Jin XW, Cash J, Kennedy AW. Human papillomavirus typing and the reduction of cervical cancer risk. Cleveland Clin. J. Med. 1999; 66: 533– 539. 10535179
  37. [39]Juneja A, Sehgal A, Mitra AB, Pandey A. A survey on risk factors associated with cervical cancer. Indian J Cancer. 2003; 40(1): 15– 22. 14716127
  38. [40]Kim HJ, Kim H-J. Current status and future prospects for human papillomavirus vaccines. Arch. Pharm. Res. 2017: 1– 14. 28875439
  39. [41]Kivistic A, Lang K, Baili P, Anttila A, Veerus P. Women's knowledge about cervical cancer risk factors, screening, and reasons for non-participation in cervical cancer screening programme in Estonia. BMC Women's Health. 2011; 11: 43. 21951661 PMC3192747
  40. [42]Leinonen MK, Nieminen P, Lönnberg S, Malila N, Hakama M, Pokhrel A, Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirua DNA testing: prospective randomised trial in Finland. BMJ. 2012; 345; e7789. 23197596 PMC3509927
  41. [43]Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int. J. Cancer 2011; 128: 927– 935. 20473886
  42. [44]Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013; 121: 829– 46. 23635684
  43. [45]Moscicki AB, Palefsky J, Smith G, Siboshski S, Schoolnik G. Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. Obstst. Gynecol. 1993; 82: 578– 585. 8397358
  44. [46]Munagala R, Kausar H, Munjal C, Gupta RC. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis 2011; 32: 1697– 1705. 21859835
  45. [47]Okunade KS, Nwogu CM, Oluwole AA, Anorlu RI. Prevalence and risk factors for genital high-risk human papillomavirus infection among women attending the out-patient clinics of a university teaching hospital in Lagos, Nigeria. The Pan African Medical Journal. 2017; 28: 227. 29629013 PMC5882206
  46. [48]Okunade KS, Sunmonu O, Osanyin GE, Oluwole AA. Knowledge and Acceptability of Human Papillomavirus Vaccination among Women Attending the Gynaecological Outpatient Clinics of a University Teaching Hospital in Lagos, Nigeria. J Trop Med. 2017; 2017: 8586459 29410683 PMC5749286
  47. [49]Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 1993; 12: 186– 192. 8463044
  48. [50]Perlman S, Wamai RG, Bain PA, Welty T, Welty E, Ogembo JG. Knowledge and awareness of HPV vaccine and acceptability to vaccinate in sub-Saharan Africa: A systematic review. PLoS ONE. 2014; 9(3): e90912. 24618636 PMC3949716
  49. [51]Philips DH, NiShé M Smoking-related DNA adducts in human cervical biopsies. IARC Sci. Publ. 1993; 124: 327– 330. 8225502
  50. [52]Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008; 9(10): 929– 936. 18805733
  51. [54]Rybicki EP. Plant-based vaccines against viruses. Virol. J. 2014; 11(1): 205. 25465382 PMC4264547
  52. [55]Sapp M, Volpers C, Muller M, Streck RE. Organization of the major and minor capsid proteins in human papillomavirus type 33 virus-like particles. J. Gen. Virol. 1995; 76: 2407– 2412. 7561785
  53. [56]Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. Am J Clin Pathol 2012; 137: 516– 42. 22431528
  54. [57]Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890– 907. 17826171
  55. [58]Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol. Biomarkers Prev. 2013; 22: 553– 560. 23549399 PMC3711590
  56. [59]Shields TS, Brinton LA, Burk RD, Wang SS, Weinstein SJ, Ziegler RG A case-control study of risk factors for invasive cervical cancer among US women exposed to oncogenic types of human papillomavirus. Cancer Epidemiol Biomarkers Prev. 2004; 13(10): 1574– 1582. 15466972
  57. [60]Singh DK, Anastos K, Hoover DR, Burk RD, Shi Q, Ngendahayo L, Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis 2009; 199(12): 1851– 1861. 19435429 PMC2814215
  58. [61]Stanley MA, Pett MR, Coleman N. HPV: from infection to cancer. Biochemical Society Transactions. 2007; 35(6): 1456– 1460. 18031245
  59. [62]Syrjänen KJ Natural history of genital human papillomavirus infections In Lacey C (ed.), Papillomavirus reviews. Leeds University Press, Leeds, United Kingdom 1996: p. 189– 206.
  60. [63]Torrisi A, Del Mistro A, Onnis GL, Merlin F, Bertorelle R, Minucci D. Colposcopy, cytology and HPV testing in HIV-positive and HIV-negative women. Eur. J. Gynecol. Oncol. 2000; 21: 168– 172. 10843478
  61. [64]Unger ER, Eliav B. Human Papillomavirus and Cervical Cancer Emerg Infect Dis. 2004; 10(11): 2031– 2032. 16010736 PMC3329022
  62. [65]Vici P Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev. Vaccin. 2016; 15(10): 1327– 1336. PMC5152541 27063030
  63. [66]Villa LL. Human papillomaviruses and cervical cancer. Adv. Cancer Res. 1996; 71: 321– 341. 9111869
  64. [67]Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12– 19. 10451482
  65. [68]WHO, “ World Health Organization Human papillomavirus vaccines WHO position paper,” The Weekly Epidemiological Record. 2009; 15(84): 117– 132.
  66. [69]WHO – World Health Organization. HPV vaccination In: Comprehensive Cervical Cancer Control - A guide to essential practice. 2nd ed. World Health Organization 2014 Geneva, Switzerland: WHO Press; p110– 128. 25642554
  67. [70]Williams VM, Filippova M, Soto U, Duerksen-Hughes PJ. HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Fut Virol. 2011; 6: 45– 57. PMC3037184 21318095
  68. [71]Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015; 136(2): 189– 97. 25579108
  69. [72]Yang A Perspectives for therapeutic HPV vaccine development. J. Biomed. Sci. 2016; 23(1): 75. 27809842 PMC5096309
  70. [73]Yang X, Jin G, Nakao Y, Rahimtula M, Pater MM, Pater A. Malignant transformation of HPV-16 immortalized human endocervical cells by cigarette smoke condensate and characterization of multistage carcinogenesis. Int J. Cancer 1996; 65: 338– 344. 8575855
  71. [74]Zhang J-J, Cao X-C, Zheng X-Y, Wang H-Y, and Li Y-W. Feasibility study of a human papillomavirus E6 and E7 oncoprotein test for the diagnosis of cervical precancer and cancer. J Int Med Res. 2018; 46(3): 1033– 1042. 29322839 PMC5972251

Cited by

Sorted by citations

Authors
Okunade, K. S.
Affiliations
University of Lagos (NG)
Corresponding author
Okunade, Kehinde Sharafadeen
ORCID
Okunade, Kehinde Sharafadeen
Venue
Journal of Obstetrics and Gynaecology
Publisher
Informa UK Limited
Published
2019-09-10
Volume
40
Issue
5
Pages
602-608
ISSN
  • 0144-3615 (ISSN-L)
  • 1364-6893
DOI
10.1080/01443615.2019.1634030
PMC
PMC7062568
OpenAlex
W2944361240
Cited by
809
References
2
Citations by year
2026: 133 · 2025: 227 · 2024: 232 · 2023: 111 · 2022: 67 · 2021: 29 · 2020: 9 · 2019: 1
FWCI
3.90
Type
journal article
Language
en
Update notices
correction (2020-01-31)
Open access
Locations
  • Journal of Obstetrics and Gynaecology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • IntechOpen (submittedVersion, cc-by)
Funders
  • National Institutes of Health
  • National Cancer Institute (U54CA221205)
  • Fogarty International Center (D43TW010134, D43TW010543)
  • CHIST-ERA
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
Keywords
human papillomavirus, cervical cancer, high-risk HPV, persistent HPV infection, HPV oncogenicity, HPV vaccination, HPV testing, cervical cancer screening, HPV-associated cancers, oropharyngeal cancer, anogenital cancer
MeSH terms
Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Female, Humans, Mass Screening, Risk Factors, Papillomavirus Infections, Alphapapillomavirus, Papillomavirus Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review